Natural language signatures of psilocybin microdosing
- PMID: 35676541
- DOI: 10.1007/s00213-022-06170-0
Natural language signatures of psilocybin microdosing
Abstract
Rationale: Serotonergic psychedelics are being studied as novel treatments for mental health disorders and as facilitators of improved well-being, mental function, and creativity. Recent studies have found mixed results concerning the effects of low doses of psychedelics ("microdosing") on these domains. However, microdosing is generally investigated using instruments designed to assess larger doses of psychedelics, which might lack sensitivity and specificity for this purpose.
Objectives: Determine whether unconstrained speech contains signatures capable of identifying the acute effects of psilocybin microdoses.
Methods: Natural speech under psilocybin microdoses (0.5 g of psilocybin mushrooms) was acquired from thirty-four healthy adult volunteers (11 females: 32.09 ± 3.53 years; 23 males: 30.87 ± 4.64 years) following a double-blind and placebo-controlled experimental design with two measurement weeks per participant. On Wednesdays and Fridays of each week, participants consumed either the active dose (psilocybin) or the placebo (edible mushrooms). Features of interest were defined based on variables known to be affected by higher doses: verbosity, semantic variability, and sentiment scores. Machine learning models were used to discriminate between conditions. Classifiers were trained and tested using stratified cross-validation to compute the AUC and p-values.
Results: Except for semantic variability, these metrics presented significant differences between a typical active microdose and the inactive placebo condition. Machine learning classifiers were capable of distinguishing between conditions with high accuracy (AUC [Formula: see text] 0.8).
Conclusions: These results constitute first evidence that low doses of serotonergic psychedelics can be identified from unconstrained natural speech, with potential for widely applicable, affordable, and ecologically valid monitoring of microdosing schedules.
Keywords: Language; Machine learning; Microdosing; Psilocybin; Psychedelics.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research.J Psychopharmacol. 2024 Aug;38(8):701-711. doi: 10.1177/02698811241254831. Epub 2024 Jun 14. J Psychopharmacol. 2024. PMID: 38877715 Free PMC article. Review.
-
Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study.Transl Psychiatry. 2022 Aug 2;12(1):307. doi: 10.1038/s41398-022-02039-0. Transl Psychiatry. 2022. PMID: 35918311 Free PMC article. Clinical Trial.
-
Self-blinding citizen science to explore psychedelic microdosing.Elife. 2021 Mar 2;10:e62878. doi: 10.7554/eLife.62878. Elife. 2021. PMID: 33648632 Free PMC article.
-
Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention.J Psychopharmacol. 2022 Jan;36(1):85-96. doi: 10.1177/0269881120953994. Epub 2020 Oct 8. J Psychopharmacol. 2022. PMID: 33591231
-
Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives.Transcult Psychiatry. 2022 Oct;59(5):665-674. doi: 10.1177/13634615221119386. Epub 2022 Aug 29. Transcult Psychiatry. 2022. PMID: 36031848 Review.
Cited by
-
Psilocybin: From Psychiatric Pariah to Perceived Panacea.Am J Psychiatry. 2025 Jan 1;182(1):54-78. doi: 10.1176/appi.ajp.20230682. Am J Psychiatry. 2025. PMID: 39741437 Review.
-
Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomized semi-naturalistic-lab feasibility study.Philos Trans R Soc Lond B Biol Sci. 2024 Dec 2;379(1915):20230095. doi: 10.1098/rstb.2023.0095. Epub 2024 Oct 21. Philos Trans R Soc Lond B Biol Sci. 2024. PMID: 39428872 Clinical Trial.
-
Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research.J Psychopharmacol. 2024 Aug;38(8):701-711. doi: 10.1177/02698811241254831. Epub 2024 Jun 14. J Psychopharmacol. 2024. PMID: 38877715 Free PMC article. Review.
References
-
- Agurto C, Cecchi GA, Norel R, Ostrand R, Kirkpatrick M, Baggott MJ, Wardle MC, Wit H, Bedi G (2020) Detection of acute 3,4-methylenedioxymethamphetamine (MDMA) effects across protocols using automated natural language processing. Neuropsychopharmacology 45(5):823–832. https://doi.org/10.1038/s41386-020-0620-4 - DOI - PubMed - PMC
-
- Anderson T, Petranker R, Christopher A, Rosenbaum D, Weissman C, Dinh-Williams LA, Hui K, Hapke E (2019a) Psychedelic microdosing benefits and challenges: an empirical codebook. Harm Reduct J 16(1):43. https://doi.org/10.1186/s12954-019-0308-4 - DOI - PubMed - PMC
-
- Anderson T, Petranker R, Rosenbaum D, Weissman CR, Dinh-Williams LA, Hui K, Hapke E, Farb NAS (2019b) Microdosing psychedelics: personality, mental health, and creativity differences in microdosers. Psychopharmacology 236(2):731–740. https://doi.org/10.1007/s00213-018-5106-2 - DOI - PubMed
-
- Babu NV, Kanaga EGM (2022) Sentiment analysis in social media data for depression detection using artificial intelligence: a review. SN Comput Sci 3(1):74. https://doi.org/10.1007/s42979-021-00958-1 - DOI - PubMed
-
- Bedi G, Cecchi GA, Slezak DF, Carrillo F, Sigman M, de Wit H (2014) A window into the intoxicated mind? Speech as an index of psychoactive drug effects. Neuropsychopharmacology 39(10):2340–2348. https://doi.org/10.1038/npp.2014.80 - DOI - PubMed - PMC
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical